Serum NT-proBNP as a predictive biomarker for bronchopulmonary dysplasia and mortality in preterm infants with patent ductus arteriosus: A prospective validation study

Key Points

• The study aims to evaluate serum NT-proBNP as a predictive biomarker for bronchopulmonary dysplasia (BPD) and mortality in preterm infants with patent ductus arteriosus (PDA).
• Prospective validation study
• NT-proBNP levels were measured within 72 hours and on days 8-9 of life in preterm infants with PDA diameter >1.5 mm.
• Predictive values for BPD and mortality were assessed using sensitivity and specificity metrics.
• At <72 hours, the sensitivity of NT-proBNP for predicting BPD/death was 62.8% and specificity was 83.3%.
• At days 8-9, sensitivity increased to 72.7% and specificity to 88.9%.
• Overall, NT-proBNP showed a moderate predictive value, especially on days 8-9 for the development of BPD and mortality.